Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:The new occurrence of antiphospholipid syndrome in severe COVID-19 cases with pneumonia and vascular thrombosis could explain the post-COVID syndrome
Avtorji:ID Zlatković Švenda, Mirjana (Avtor)
ID Rašić, Melanija (Avtor)
ID Ovuka, Milica (Avtor)
ID Pavlov Dolijanović, Slavica (Avtor)
ID Atanasković Popović, Marija (Avtor)
ID Ogrič, Manca (Avtor)
ID Žigon, Polona (Avtor)
ID Sodin-Šemrl, Snežna (Avtor)
ID Zdravković, Marija (Avtor)
ID Radunović, Goran (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,28 MB)
MD5: F65DDDCAB9503E53882FCEE7DA534088
 
URL URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2227-9059/13/2/516
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Introduction: The classification of antiphospholipid syndrome (APS) comprises clinical criteria (vascular thrombosis or obstetric complications throughout life) and laboratory criteria (antiphospholipid antibodies (aPLs) positivity, confirmed at least twice at 12-week interval). Methods: In 100 patients admitted to the hospital with COVID-19 pneumonia, thrombosis and pregnancy complications were recorded during the hospital stay and in personal medical history. They were tested for nine types of aPLs at four time points (admission, deterioration, discharge, and 3-month follow-up): anticardiolipin (aCL), anti-β2-glycoproteinI (anti-β2GPI), and antiphosphatidylserine/prothrombin (aPS/PT) isotypes IgM/IgG/IgA. Results: During hospitalization, aPLs were detected at least once in 51% of patients. All 7% of deceased patients tested negative for aPLs upon admission, and only one patient became aCL IgG positive as his condition worsened. In 83.3% of patients, intrahospital thrombosis was not related to aPLs. One patient with pulmonary artery and cerebral artery thrombosis was given an APS diagnosis (triple aPLs positivity on admission, double on follow-up). Personal anamnesis (PA) for thromboembolism was verified in 10 patients, all of whom tested negative for aPLs at admission; however, transition to aPLs positivity at discharge (as the disease subsided) was seen in 60% of patients: three of six with arterial thrombosis (at follow-up, two did not appear, and one was negativized) and three of four with deep vein thrombosis (one was confirmed at follow-up and diagnosed with APS, one was negativized, and one did not appear). At admission, the majority of the aPLs were of the aCL IgG class (58.8%). Unexpectedly, as the COVID-19 disease decreased, anti-β2GPI IgG antibodies (linked with thromboses) became newly positive at discharge (14.9%), as confirmed at follow-up (20.8%). Conclusion: The incidence of APS in our cohort was 2.0%, whereas in the general population, it ranges from 0.001% to 0.002%. The incidence might have increased even more if the four aPLs-positive patients with intrahospital thrombosis/history of thrombosis had attended follow-up. Recommendation: All patients with severe COVID-19 or post-COVID syndrome should be evaluated for current/previous thrombosis and tested for aPLs at least twice: at admission to the hospital and at discharge, then retested 3 months later in positive cases in order to be given the appropriate therapy.
Ključne besede:COVID-19, SARS-CoV2, anti-phosphatidylserine-prothrombin (aPS/PT) antibodies, anti-β2-glycoprotein I (anti-β2GPI) antibodies, anticardiolipin (aCL) antibodies, antiphospholipid antibodies (aPLs), antiphospholipid syndrome, immunology, post-COVID syndrome, vascular thrombosis
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:str. 1-21
Številčenje:Vol. 13, iss. 2, [article no.] 516
PID:20.500.12556/DiRROS-24485 Novo okno
UDK:616.9
ISSN pri članku:2227-9059
DOI:10.3390/biomedicines13020516 Novo okno
COBISS.SI-ID:228779523 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 12. 3. 2025;
Datum objave v DiRROS:01.12.2025
Število ogledov:89
Število prenosov:44
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Biomedicines
Skrajšan naslov:Biomedicines
Založnik:MDPI AG
ISSN:2227-9059
COBISS.SI-ID:523006745 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0314-2022
Naslov:Sistemske avtoimunske bolezni

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:protitelesa proti fosfatidilserin-protrombinu (aPS/PT), protitelesa proti β2-glikoproteinu I (anti-β2GPI), protitelesa proti kardiolipinu (aCL), antifosfolipidna protitelesa (aPL), antifosfolipidni sindrom, imunologija, post-COVID sindrom, vaskularna tromboza


Nazaj